FDA Approves MUCUS RELIEF — CHAIN DRUG MARKETING ASSOCIATION, INC.

The FDA has approved a 600 mg guaifenesin immediate-release tablet application (No. ANDA213420) for CHAIN DRUG MARKETING ASSOCIATION, INC., relieving the on-tap supply strain for this standard expectorant and potentially expanding profitable shelf space for the entrenched manufacturer. This approval solidifies the provider's distribution network capabilities amid the competitive OTC therapeutic landscape, likely reinforcing market access and stabilizing pricing within the lower-cost oral dosage segment.